ebenbuild.com

What It Is

Ebenbuild’s core product, Twinhale, is an in silico digital twin tool/service for inhaled drug delivery. Using patient-specific lung geometries and virtual patient cohorts, it simulates regional drug deposition in the lungs under different inhalation devices, formulations, doses, and operating parameters, helping R&D teams obtain quantitative evidence before entering clinical trials.

Core Capabilities and Outputs

The main value proposition emphasized in the copy is that Twinhale can compress an almost unlimited design space of devices and parameters into a small number of data-characterized options. It is suitable for evaluating how nebulizers, inhaler configurations, dosing levels, and formulation strategies affect local lung dose, while accounting for patient variability and process uncertainty. Outputs are typically quantitative, actionable deposition insights, with the official description stating that results can be delivered in about 2 weeks after the run.

Pricing and Service Model

The website does not disclose standard packages, per-project pricing, or subscription fees. The workflow appears closer to a customized research service: first, a 1-hour meeting is scheduled to clarify requirements; Ebenbuild then designs the in silico trial and selects the digital cohort; after the client reviews the proposal, simulations and analysis are carried out. As a result, procurement requires commercial discussion, and value for money is difficult to assess based only on public information.

Pros and Cons

Its strengths are that it is highly vertical and focused on a key pain point in inhaled drug development. It can help de-risk device selection, dose optimization, and trial design before clinical studies, while aligning with regulatory trends from the FDA and EMA around NAMs, MIDD, and model-informed evidence. The limitations are also clear: the public copy does not provide model accuracy, validation data, applicability boundaries, API information, data privacy details, or Chinese-language support. Unlike a general-purpose SaaS product, it is unlikely to offer easy self-service trials.

Who It’s For and Access from China

Twinhale is better suited for pharmaceutical companies, inhaled therapy innovators, nebulizer/inhaler device teams, and preclinical teams that need evidence on pulmonary deposition. Its accessibility from China cannot be determined from the available copy, and payment methods are not disclosed. For Chinese teams considering adoption, key items to confirm include cross-border access, data compliance, contract payment arrangements, how sample/patient data is handled, and whether there are local alternatives or collaboration options with universities/simulation software providers.